Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials
•Current pharmacological treatment for alcoholism remains unsatisfactory.•Varenicline may have a medium effect size in decreasing alcohol consumption.•Varenicline is well tolerable and accepted.•Varenicline may be an option for the treatment of alcoholism. Current pharmacological treatment for alcoh...
Gespeichert in:
Veröffentlicht in: | Drug and alcohol dependence 2019-12, Vol.205, p.107631-107631, Article 107631 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 107631 |
---|---|
container_issue | |
container_start_page | 107631 |
container_title | Drug and alcohol dependence |
container_volume | 205 |
creator | Oon-arom, Awirut Likhitsathain, Surinporn Srisurapanont, Manit |
description | •Current pharmacological treatment for alcoholism remains unsatisfactory.•Varenicline may have a medium effect size in decreasing alcohol consumption.•Varenicline is well tolerable and accepted.•Varenicline may be an option for the treatment of alcoholism.
Current pharmacological treatment for alcoholism remains unsatisfactory. While there have been several clinical trials investigating the efficacy and safety of the therapeutic use of varenicline in alcoholism, no definitive review of this topic has been carried out. This systematic review aimed to determine the efficacy and acceptability of the use of varenicline in treating alcoholism.
This systematic review included double-blinded, randomized, placebo-controlled trials reporting heavy drinking days, amount of alcohol consumption, overall dropouts, or dropouts due to adverse events. We searched PubMed, Scopus, Web of Science, ClinicalTrials.gov, and the Cochrane Library in January 2019. We independently selected the trials and assessed the quality of included studies. We calculated standardized mean differences on heavy drinking days and the amount of alcohol consumption. We calculated the relative risks for dropout rate. All data were pooled using random-effects models.
This systematic review included nine double-blind, randomized, placebo-controlled trials (N = 585). The study duration ranged from 4 to 13 weeks. Varenicline therapy was not superior to placebo in decreasing heavy drinking days but significantly superior to placebo in decreasing alcohol consumption. There were no statistically significant differences between groups on dropout rates due to any reason or due to adverse events.
Varenicline therapy is effective in decreasing alcohol consumption over a period of time. It may be an option for decreasing heavy drinking days in patients with alcoholism. It is a well-accepted medication for alcoholism. More studies are needed to determine if varenicline is effective in decreasing heavy drinking. |
doi_str_mv | 10.1016/j.drugalcdep.2019.107631 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2311925578</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0376871619304089</els_id><sourcerecordid>2330764864</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-dea6c015f5e566d3a8c5b49da17e408d46ce14c99f44e17231717ad7b94435103</originalsourceid><addsrcrecordid>eNqFkUGLFDEQhYMoOK7-h4AXLz0m0-mk421ddlVY8KLnUFOp1gzpzphkVtqLf92MIwherEtB8b1XVD3GuBRbKaR-fdj6fPoCET0dtzshbRsb3ctHbCNHYzshlH7MNqI3uhuN1E_Zs1IOopW2YsN-3k5TQMCVw-I5INKxwj7EUFeeJv4AmZaAMSzEp5R525O-phjK_IZf87KWSjPUgDzTQ6Dvv01mqtDBAnEtoZxNcpumOfwg32Faak4xkuc1B4jlOXsytUYv_vQr9vnu9tPN--7-47sPN9f3HfbG1s4TaBRymAYatPY9jDjslfUgDSkxeqWRpEJrJ6VIml0vjTTgzd4q1Q9S9Ffs1cX3mNO3E5Xq5lCQYoSF0qm4ppB2NwxmbOjLf9BDOuV2z5nq23PVqFWjxguFOZWSaXLHHGbIq5PCnZNxB_c3GXdOxl2SadK3Fym1g9vbsisYaEHyIRNW51P4v8kvR3Od3A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2330764864</pqid></control><display><type>article</type><title>Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials</title><source>Elsevier ScienceDirect Journals Complete</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><creator>Oon-arom, Awirut ; Likhitsathain, Surinporn ; Srisurapanont, Manit</creator><creatorcontrib>Oon-arom, Awirut ; Likhitsathain, Surinporn ; Srisurapanont, Manit</creatorcontrib><description>•Current pharmacological treatment for alcoholism remains unsatisfactory.•Varenicline may have a medium effect size in decreasing alcohol consumption.•Varenicline is well tolerable and accepted.•Varenicline may be an option for the treatment of alcoholism.
Current pharmacological treatment for alcoholism remains unsatisfactory. While there have been several clinical trials investigating the efficacy and safety of the therapeutic use of varenicline in alcoholism, no definitive review of this topic has been carried out. This systematic review aimed to determine the efficacy and acceptability of the use of varenicline in treating alcoholism.
This systematic review included double-blinded, randomized, placebo-controlled trials reporting heavy drinking days, amount of alcohol consumption, overall dropouts, or dropouts due to adverse events. We searched PubMed, Scopus, Web of Science, ClinicalTrials.gov, and the Cochrane Library in January 2019. We independently selected the trials and assessed the quality of included studies. We calculated standardized mean differences on heavy drinking days and the amount of alcohol consumption. We calculated the relative risks for dropout rate. All data were pooled using random-effects models.
This systematic review included nine double-blind, randomized, placebo-controlled trials (N = 585). The study duration ranged from 4 to 13 weeks. Varenicline therapy was not superior to placebo in decreasing heavy drinking days but significantly superior to placebo in decreasing alcohol consumption. There were no statistically significant differences between groups on dropout rates due to any reason or due to adverse events.
Varenicline therapy is effective in decreasing alcohol consumption over a period of time. It may be an option for decreasing heavy drinking days in patients with alcoholism. It is a well-accepted medication for alcoholism. More studies are needed to determine if varenicline is effective in decreasing heavy drinking.</description><identifier>ISSN: 0376-8716</identifier><identifier>EISSN: 1879-0046</identifier><identifier>DOI: 10.1016/j.drugalcdep.2019.107631</identifier><language>eng</language><publisher>Lausanne: Elsevier B.V</publisher><subject>Acceptability ; Alcohol ; Alcohol use ; Alcoholic beverages ; Alcoholism ; Alcohols ; Clinical research ; Clinical trials ; Critical incidents ; Dependence ; Drinking ; Drinking behavior ; Dropping out ; Drug abuse ; Drug therapy ; Drugs ; Efficacy ; Heavy drinkers ; Meta-analysis ; Quality assessment ; Randomization ; Risk assessment ; Risk factors ; School dropout programs ; School dropouts ; Statistical analysis ; Substance abuse treatment ; Systematic review ; Therapy ; Treatment methods ; Varenicline</subject><ispartof>Drug and alcohol dependence, 2019-12, Vol.205, p.107631-107631, Article 107631</ispartof><rights>2019 Elsevier B.V.</rights><rights>Copyright Elsevier Science Ltd. Dec 1, 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c379t-dea6c015f5e566d3a8c5b49da17e408d46ce14c99f44e17231717ad7b94435103</citedby><cites>FETCH-LOGICAL-c379t-dea6c015f5e566d3a8c5b49da17e408d46ce14c99f44e17231717ad7b94435103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.drugalcdep.2019.107631$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,30999,45995</link.rule.ids></links><search><creatorcontrib>Oon-arom, Awirut</creatorcontrib><creatorcontrib>Likhitsathain, Surinporn</creatorcontrib><creatorcontrib>Srisurapanont, Manit</creatorcontrib><title>Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials</title><title>Drug and alcohol dependence</title><description>•Current pharmacological treatment for alcoholism remains unsatisfactory.•Varenicline may have a medium effect size in decreasing alcohol consumption.•Varenicline is well tolerable and accepted.•Varenicline may be an option for the treatment of alcoholism.
Current pharmacological treatment for alcoholism remains unsatisfactory. While there have been several clinical trials investigating the efficacy and safety of the therapeutic use of varenicline in alcoholism, no definitive review of this topic has been carried out. This systematic review aimed to determine the efficacy and acceptability of the use of varenicline in treating alcoholism.
This systematic review included double-blinded, randomized, placebo-controlled trials reporting heavy drinking days, amount of alcohol consumption, overall dropouts, or dropouts due to adverse events. We searched PubMed, Scopus, Web of Science, ClinicalTrials.gov, and the Cochrane Library in January 2019. We independently selected the trials and assessed the quality of included studies. We calculated standardized mean differences on heavy drinking days and the amount of alcohol consumption. We calculated the relative risks for dropout rate. All data were pooled using random-effects models.
This systematic review included nine double-blind, randomized, placebo-controlled trials (N = 585). The study duration ranged from 4 to 13 weeks. Varenicline therapy was not superior to placebo in decreasing heavy drinking days but significantly superior to placebo in decreasing alcohol consumption. There were no statistically significant differences between groups on dropout rates due to any reason or due to adverse events.
Varenicline therapy is effective in decreasing alcohol consumption over a period of time. It may be an option for decreasing heavy drinking days in patients with alcoholism. It is a well-accepted medication for alcoholism. More studies are needed to determine if varenicline is effective in decreasing heavy drinking.</description><subject>Acceptability</subject><subject>Alcohol</subject><subject>Alcohol use</subject><subject>Alcoholic beverages</subject><subject>Alcoholism</subject><subject>Alcohols</subject><subject>Clinical research</subject><subject>Clinical trials</subject><subject>Critical incidents</subject><subject>Dependence</subject><subject>Drinking</subject><subject>Drinking behavior</subject><subject>Dropping out</subject><subject>Drug abuse</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Efficacy</subject><subject>Heavy drinkers</subject><subject>Meta-analysis</subject><subject>Quality assessment</subject><subject>Randomization</subject><subject>Risk assessment</subject><subject>Risk factors</subject><subject>School dropout programs</subject><subject>School dropouts</subject><subject>Statistical analysis</subject><subject>Substance abuse treatment</subject><subject>Systematic review</subject><subject>Therapy</subject><subject>Treatment methods</subject><subject>Varenicline</subject><issn>0376-8716</issn><issn>1879-0046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNqFkUGLFDEQhYMoOK7-h4AXLz0m0-mk421ddlVY8KLnUFOp1gzpzphkVtqLf92MIwherEtB8b1XVD3GuBRbKaR-fdj6fPoCET0dtzshbRsb3ctHbCNHYzshlH7MNqI3uhuN1E_Zs1IOopW2YsN-3k5TQMCVw-I5INKxwj7EUFeeJv4AmZaAMSzEp5R525O-phjK_IZf87KWSjPUgDzTQ6Dvv01mqtDBAnEtoZxNcpumOfwg32Faak4xkuc1B4jlOXsytUYv_vQr9vnu9tPN--7-47sPN9f3HfbG1s4TaBRymAYatPY9jDjslfUgDSkxeqWRpEJrJ6VIml0vjTTgzd4q1Q9S9Ffs1cX3mNO3E5Xq5lCQYoSF0qm4ppB2NwxmbOjLf9BDOuV2z5nq23PVqFWjxguFOZWSaXLHHGbIq5PCnZNxB_c3GXdOxl2SadK3Fym1g9vbsisYaEHyIRNW51P4v8kvR3Od3A</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Oon-arom, Awirut</creator><creator>Likhitsathain, Surinporn</creator><creator>Srisurapanont, Manit</creator><general>Elsevier B.V</general><general>Elsevier Science Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20191201</creationdate><title>Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials</title><author>Oon-arom, Awirut ; Likhitsathain, Surinporn ; Srisurapanont, Manit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-dea6c015f5e566d3a8c5b49da17e408d46ce14c99f44e17231717ad7b94435103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acceptability</topic><topic>Alcohol</topic><topic>Alcohol use</topic><topic>Alcoholic beverages</topic><topic>Alcoholism</topic><topic>Alcohols</topic><topic>Clinical research</topic><topic>Clinical trials</topic><topic>Critical incidents</topic><topic>Dependence</topic><topic>Drinking</topic><topic>Drinking behavior</topic><topic>Dropping out</topic><topic>Drug abuse</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Efficacy</topic><topic>Heavy drinkers</topic><topic>Meta-analysis</topic><topic>Quality assessment</topic><topic>Randomization</topic><topic>Risk assessment</topic><topic>Risk factors</topic><topic>School dropout programs</topic><topic>School dropouts</topic><topic>Statistical analysis</topic><topic>Substance abuse treatment</topic><topic>Systematic review</topic><topic>Therapy</topic><topic>Treatment methods</topic><topic>Varenicline</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oon-arom, Awirut</creatorcontrib><creatorcontrib>Likhitsathain, Surinporn</creatorcontrib><creatorcontrib>Srisurapanont, Manit</creatorcontrib><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Drug and alcohol dependence</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oon-arom, Awirut</au><au>Likhitsathain, Surinporn</au><au>Srisurapanont, Manit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials</atitle><jtitle>Drug and alcohol dependence</jtitle><date>2019-12-01</date><risdate>2019</risdate><volume>205</volume><spage>107631</spage><epage>107631</epage><pages>107631-107631</pages><artnum>107631</artnum><issn>0376-8716</issn><eissn>1879-0046</eissn><abstract>•Current pharmacological treatment for alcoholism remains unsatisfactory.•Varenicline may have a medium effect size in decreasing alcohol consumption.•Varenicline is well tolerable and accepted.•Varenicline may be an option for the treatment of alcoholism.
Current pharmacological treatment for alcoholism remains unsatisfactory. While there have been several clinical trials investigating the efficacy and safety of the therapeutic use of varenicline in alcoholism, no definitive review of this topic has been carried out. This systematic review aimed to determine the efficacy and acceptability of the use of varenicline in treating alcoholism.
This systematic review included double-blinded, randomized, placebo-controlled trials reporting heavy drinking days, amount of alcohol consumption, overall dropouts, or dropouts due to adverse events. We searched PubMed, Scopus, Web of Science, ClinicalTrials.gov, and the Cochrane Library in January 2019. We independently selected the trials and assessed the quality of included studies. We calculated standardized mean differences on heavy drinking days and the amount of alcohol consumption. We calculated the relative risks for dropout rate. All data were pooled using random-effects models.
This systematic review included nine double-blind, randomized, placebo-controlled trials (N = 585). The study duration ranged from 4 to 13 weeks. Varenicline therapy was not superior to placebo in decreasing heavy drinking days but significantly superior to placebo in decreasing alcohol consumption. There were no statistically significant differences between groups on dropout rates due to any reason or due to adverse events.
Varenicline therapy is effective in decreasing alcohol consumption over a period of time. It may be an option for decreasing heavy drinking days in patients with alcoholism. It is a well-accepted medication for alcoholism. More studies are needed to determine if varenicline is effective in decreasing heavy drinking.</abstract><cop>Lausanne</cop><pub>Elsevier B.V</pub><doi>10.1016/j.drugalcdep.2019.107631</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0376-8716 |
ispartof | Drug and alcohol dependence, 2019-12, Vol.205, p.107631-107631, Article 107631 |
issn | 0376-8716 1879-0046 |
language | eng |
recordid | cdi_proquest_miscellaneous_2311925578 |
source | Elsevier ScienceDirect Journals Complete; Applied Social Sciences Index & Abstracts (ASSIA) |
subjects | Acceptability Alcohol Alcohol use Alcoholic beverages Alcoholism Alcohols Clinical research Clinical trials Critical incidents Dependence Drinking Drinking behavior Dropping out Drug abuse Drug therapy Drugs Efficacy Heavy drinkers Meta-analysis Quality assessment Randomization Risk assessment Risk factors School dropout programs School dropouts Statistical analysis Substance abuse treatment Systematic review Therapy Treatment methods Varenicline |
title | Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T02%3A03%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20acceptability%20of%20varenicline%20for%20alcoholism:%20A%20systematic%20review%20and%20meta-analysis%20of%20randomized-controlled%20trials&rft.jtitle=Drug%20and%20alcohol%20dependence&rft.au=Oon-arom,%20Awirut&rft.date=2019-12-01&rft.volume=205&rft.spage=107631&rft.epage=107631&rft.pages=107631-107631&rft.artnum=107631&rft.issn=0376-8716&rft.eissn=1879-0046&rft_id=info:doi/10.1016/j.drugalcdep.2019.107631&rft_dat=%3Cproquest_cross%3E2330764864%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2330764864&rft_id=info:pmid/&rft_els_id=S0376871619304089&rfr_iscdi=true |